Table 1 Sample’s baseline characteristics, according to the presence of Clinical Lipodystrophy (CL)
With CL | Without CL | P value | |
|---|---|---|---|
n (%) | 115 (52.3) | 105 (47.7) | |
Sex [n (%)] | 0.099 | ||
Male | 76 (66.1) | 57 (54.3) | |
Female | 39 (33.9) | 48 (45.7) | |
Age [years, mean (SD)] | 47.5 (11.3) | 43.8 (11.5) | 0.017 |
Duration of HIV infection [years, median (IR)] | 9 (5) | 6 (6) | 0.001 |
cART [years, median (IR)] | 8 (5) | 5 (5.5) | < 0.001 |
Weight [Kg, mean (SD)] | 64.1 (12.8) | 73.9 (12.6) | < 0.001 |
Height [m, mean (SD)] | 1.7 (0.1) | 1.7 (0.1) | 0.765 |
BMI [(kg/m2), mean (SD)] | 23.6 (3.8) | 27.2 (4.5) | < 0.001 |
Waist circumference [cm, mean (SD)] | 88.4 (10.8) | 95.1 (12.1) | < 0.001 |
CD4 cell count [cells/mm3, median (IR)] | 554 (385) | 479 (300) | 0.238 |
HIV RNA (<50) [n (%)] | 100 (100) | 92 (100) | |
Hepatitis C co-infection [n (%)] | 34 (29.8) | 30 (29.4) | 0.999 |
Hypertension [n (%)] | 45 (39.1) | 23 (21.9) | 0.009 |
HIV risk factor [n (%)] | 0.162 | ||
Intravenous drug user | 1 (25) | 3 (15.8) | |
Homosexual contact | 0 (0) | 2 (10.5) | |
Heterosexual contact | 2 (50) | 14 (73.7) | |
Others | 1 (25) | 0 (0) | |
CDC clinical categories [n (%)] | 0.389 | ||
A | 63 (54.8) | 56 (53.3) | |
B | 1 (0.9) | 4 (3.8) | |
C | 51 (44.3) | 45 (42.9) | |
ART [n (%)] | |||
IP | 61 (53) | 62 (59) | 0.447 |
NNRTI | 55 (47.8) | 47 (44.8) | 0.749 |
NRTI | 113 (98.3) | 97 (92.4) | 0.051 |
Smoking history [n (%)] | 0.032 | ||
Never | 38 (33.3) | 53 (50.5) | |
Current | 56 (49.1) | 36 (34.3) | |
Former | 20 (17.5) | 16 (15.2) | |
Total cholesterol [mg/dL, mean (SD)] | 221.9 (53.2) | 227.8 (57.8) | 0.433 |
LDL- cholesterol [mg/dL, mean (SD)] | 129.4 (48.1) | 140 (45.4) | 0.097 |
HDL- cholesterol [mg/dL, mean (SD)] | 46.5 (14.8) | 49.5 (13.3) | 0.123 |
Triglycerides [mg/dL, median (IR)] | 215.5 (214.5) | 171 (154) | 0.007 |
Statin use [n (%)] | 33 (28.7) | 13 (12.4) | 0.005 |
Fibrate use [n (%)] | 41 (35.7) | 24 (22.9) | 0.054 |